Glenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...

VS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per quarter. Challeng...

The tablets are being recalled because of the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable d...

The opportunity for domestic companies could cumulatively fetch up to a billion dollars in sales.

Hold Glenmark Pharmaceuticals Ltd. at a price target of Rs 595.0 .

Foreign outflows continued but domestic inflows remained strong and helped the indices cap losses.

Bofa-ML believes that the growth momentum in the US geography is likely to sustain beyond 6-month exclusivity for cholesterol lowering drug...

Nifty Pharma index is down over 20% from its 52-week high of 13,753.50, which indicates a bearish phase for the index. Glenmark, Cipla are ...

The US business holds the key for GNP to achieving management's growth guidance

There is some issue with IT in general as IT services exports have been falling and this is an event that will also come into RBI data soon

Shares of Glenmark gained about 3 per cent in Wednesday's trade after the company provided a bullish guidance of 18-20 per cent growing in ...

Pharma stocks are trading at extremely high valuations and, thus, could especially be vulnerable to any disappointment, says Bodke.

Glenmark Pharmaceuticals today said it is aiming for up to 30 per cent growth in revenues this fiscal to touch Rs 5,000 crore.

Aided by robust growth from its key businesses and geographies, Glenmark managed to show a strong topline growth of 34% year-on-year in the...

Glenmark Pharmaceuticals today posted a consolidated net profit of Rs 457.83 crore for the year ended March 31, 2011.

Recent developments could well be a pointer to better days ahead for Glenmark Pharma which has had a relatively poor performance in the pas...

Citi has maintained a ‘buy’ rating on Glenmark Pharmaceuticals after the company maintained its revenue and PAT guidance for FY09-10.